Despite these changes, we are pleased to announce that specific peptides remain available through our services, contingent upon a medical consultation
The FDA enforcement-discretion period that allowed mass compounding during the tirzepatide shortage ended on March 19, 2025 for 503B outsourcing facilities and February 18, 2025 for 503A pharmacies
Cartilage-focused research, including work summarized in the NIH PubMed database, explored chondrocyte effects relevant to joint repair models and suggested a potential adjunct role alongside established biologics
In contrast, methylcobalamin and adenosylcobalamin are already in active states, allowing for immediate cellular use
In a 2-year trial, acute pancreatitis was reported in 8 semaglutide-treated patients (0.27 cases per 100 patient-years) and 10 placebo-treated patients (0.33 cases per 100 patient-years), both on a background of standard of care.1 In trials of patients receiving oral semaglutide, pancreatitis was reported as a serious adverse event in 6 patients (0.1 events per 100 patient-years) receiving semaglutide versus 1 in comparator-treated patients (less than 0.1 events per 100 patient-years)